In 2024, Winner Medical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Winner Medical has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 32,222.54a | 37,185.84a | 44,374.42a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 181,006.56a | 126,718.15a | 140,960.97a | |
Total Scope 3 | 1,014,392.14a | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 26.1937a | 32.2882a | 27.22a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Winner Medical amounted to 213,229.1 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Winner Medical increased by 30.09%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Winner Medical were 32,222.54 metric tons of CO₂ equivalent (tCO₂e).a
Since 2022, Winner Medical's Scope 1 emissions have decreased by 27.38%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Winner Medical's Scope 1 emissions decreased by 13.35%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Winner Medical reported Scope 2 greenhouse gas (GHG) emissions of 181,006.56 tCO₂e without specifying the calculation method.a
Since 2022, Winner Medical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 28.41%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2023), Winner Medical's Scope 2 emissions (Unspecified Calculation Method) rose by 42.84% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2024, Winner Medical reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Winner Medical reported 1,014,392.14 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Winner Medical includes a breakdown across 12 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2024, Winner Medical reported total Scope 3 emissions of 1,014,392.14 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 90.73% of these emissions originated from upstream activities such as purchased goods and capital goods, while 9.27% came from downstream activities like product use, distribution, and end-of-life treatment.a
In 2024, Winner Medical reported emissions for 12 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Winner Medical's Scope 3 emissions were:a
In 2024, Winner Medical reported Scope 1 greenhouse gas (GHG) emissions of 32,222.54 tCO₂e and total revenues of USD 1,230 millions. This translates into an emissions intensity of 26.19 tCO₂e per millions USD.a
In 2024, Winner Medical reported a Scope 1 emissions intensity of 26.19 tCO₂e per millions USD. Compared to the peer group median of 3.12, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Winner Medical ranked 22 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Winner Medical among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2024, Winner Medical reported a total carbon footprint of 1,227,621.24 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 648.99% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Winner Medical's total carbon footprint was Scope 3 emissions, accounting for 82.63% of the company's total carbon footprint, followed by Scope 2 emissions at 14.74%.a